Tender Details

Country: Germany
Summary: Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Tofacitinib, Atc L04aa29 for the Period 09/01/2023 - 08/31/2025
DET Ref No: 86073033
Deadline: 05 Jul 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: EUR 1.00
Notice Type: Tender
Document Ref. No.: 443089-2023
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
§ 130a paragraph 8 SGB V enables the health insurance companies and pharmaceutical companies to conclude framework discount agreements for the drugs to be supplied at the expense of the statutory health insurance companies. With regard to the relevant statutory provisions on the award of public contracts, findet a regular process of active substance-related, formal award procedures according to the regulations of the 4th part of the GWB by the DAK-Gesundheit. For pharmaceuticals to be specified by the bidder in Annex 2 to the contract for the above-mentioned The active substance tofacitinib, ATC L04AA29, is intended by DAK-GesunThe aim is to conclude drug discount agreements with as many interested pharmaceutical companies as possible before new drug discount agreements come into force. A discount agreement in the context of the admission model for the above The active substance comes into force for the first time on September 1st, 2023 and ends on August 31st, 2025. Heshall automatically end upon the effective date of the exclusive contract.
Doc Title: Pharmaceutical products
Contract Type: Supplies
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Tofacitinib, Atc L04aa29 for the Period 09/01/2023 - 08/31/2025 - Germany Tender

The DAK HEALTH, a Government sector organization in Germany, has announced a new tender for Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Tofacitinib, Atc L04aa29 for the Period 09/01/2023 - 08/31/2025. This tender is published on GermanyTenders under DET Ref No: 86073033 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-07-05.

The estimated tender value is EUR 1.00, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.